6.520USD+6.520æéå€ååŒÂ 07/31, 20:00 (ET)
590.08KæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
Aspire Biopharma Holdings Inc
äž»èŠããŒã¿
6.510å§å€
6.700é«å€
9.53Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
10.79%売買å転ç
6.720忥çµå€
6.360å®å€
51.68K売買代é
æå€±é¡æ ªäŸ¡åçç
-0.09PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-259.01%ç·è³ç£å©çç
1050.36052é±é«å€
0.23åºæ¥é«æ¯ç%
-12.54MçŽå©ç
88.34Kæ ªåŒæ°
-6.97411æ ªåœããå©çïŒEPSïŒ
0.17ããŒã¿å€
-490.07%èªå·±è³æ¬å©çç
3.30952é±å®å€
5.06%æ¯ãå¹
20.28%ç²å©çç
590.08KæäŸ¡ç·é¡
0.73ãªã¹ã¯ãªã¿ãŒã³
11.27%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-30 äž»èŠã€ã³ãµã€ã
Aspire Biopharma Holdings Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯384äž202äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããäžæçã«ã¯ãæ ªäŸ¡ã¯å®å®æšç§»ãšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯è¯å¥œã§ããã¡ã³ãã¡ã³ã¿ã«ãºãåªããŠããŸãããããã¯ãã«ã«ã¯çŸåšã®ãã¬ã³ããè£ä»ãããã®ã§ã¯ãããŸãããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Aspire Biopharma Holdings Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Aspire Biopharma Holdings Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Aspire Biopharma Holdings Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
ææšî
ææš
売ã(1)
äžç«(5)
è²·ã(1)
ç§»åå¹³å
売ã(1)
äžç«(0)
è²·ã(5)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Aspire Biopharma Holdings Incã®äŒæ¥æ
å ±î
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
äŒæ¥ã³ãŒãASBP
äŒæ¥åAspire Biopharma Holdings Inc
æé«çµå¶è²¬ä»»è
ãCEOã
ãŠã§ããµã€ã
æ ªäž»çµ±èšî
ãããã質å
Aspire Biopharma Holdings IncïŒASBPïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îAspire Biopharma Holdings IncïŒASBPïŒã®çŸåšã®æ ªäŸ¡ã¯6.68ã§ãã
Aspire Biopharma Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îAspire Biopharma Holdings Incã®ãã£ãã«ãŒã·ã³ãã«ã¯ASBPã§ãã
Aspire Biopharma Holdings Incã®52é±é«å€ã¯ãããã§ããïŒ
îAspire Biopharma Holdings Incã®52é±é«å€ã¯1050.36ã§ãã
Aspire Biopharma Holdings Incã®52é±å®å€ã¯ãããã§ããïŒ
îAspire Biopharma Holdings Incã®52é±å®å€ã¯3.31ã§ãã
Aspire Biopharma Holdings Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îAspire Biopharma Holdings Incã®æäŸ¡ç·é¡ã¯590.08Kã§ãã
Aspire Biopharma Holdings Inc (ASBP) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îAspire Biopharma Holdings IncïŒASBPïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-491.27ã§ãã